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Background: Leading-edge technology such as magnetic resonance imaging (MRI) or computed tomography (CT)
often reveals mammographically and ultrasonographically occult lesions. MRI is a well-documented, effective tool to
evaluate these lesions; however, the detection rate of targeted sonography varies for MRI detected lesions, and its
significance is not well established in diagnostic strategy of MRI detected lesions. We assessed the utility of targeted
sonography for multidetector-row CT (MDCT)- or MRI-detected lesions in practice.
Methods: We retrospectively reviewed 695 patients with newly diagnosed breast cancer who were candidates for
breast conserving surgery and underwent MDCT or MRI in our hospital between January 2004 and March 2011.
Targeted sonography was performed in all MDCT- or MRI-detected lesions followed by imaging-guided biopsy.
Patient background, histopathology features and the sizes of the lesions were compared among benign, malignant
and follow-up groups.
Results: Of the 695 patients, 61 lesions in 56 patients were detected by MDCT or MRI. The MDCT- or MRI-detected
lesions were identified by targeted sonography in 58 out of 61 lesions (95.1%). Patients with pathological diagnoses
were significantly older and more likely to be postmenopausal than the follow-up patients. Pathological diagnosis
proved to be benign in 20 cases and malignant in 25. The remaining 16 lesions have been followed up.
Lesion size and shape were not significantly different among the benign, malignant and follow-up groups.
Conclusions: Approximately 95% of MDCT- or MRI-detected lesions were identified by targeted sonography, and
nearly half of these lesions were pathologically proven malignancies in this study. Targeted sonography is a useful
modality for MDCT- or MRI-detected breast lesions.Background
Diagnostic procedures are crucial for the early detection
of breast cancer. Advancements in imaging technology
now enable us to detect mammographically and ultraso-
nographically occult lesions on magnetic resonance im-
aging (MRI) or computed tomography (CT) findings.
MRI is well known for effectively detecting ductal
spreading before breast-conserving surgery with excel-
lent contrast resolution. The advantage of CT is a
shorter single acquisition with extent evaluation. In
Japan, CT is used for detecting the intraductal compo-
nent of breast cancer as an alternative to MRI [1-4].* Correspondence: satokon@m2.gyao.ne.jp
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reproduction in any medium, provided the orMultidetector-row CT (MDCT) produces imaging with a
wide range and short volume acquisition time, recom-
pounding thin slice imaging, and high-resolution and
reconstructed imaging [1,2,5].
Enhancement on MDCT or MRI is due to angiogen-
esis and increased capillary permeability [6,7]. Enhance-
ment of a lesion is an indication of proliferation
regardless of whether it is malignant or benign. These
lesions are not palpable, therefore imaging-guided biopsy
is required for definitive diagnosis. There are three avail-
able ways to perform a biopsy under imaging guidance:
stereo-guided, sonographically guided and MRI-guided
procedures.
National Comprehensive Cancer Network (NCCN)’s
guidelines have recommended the performance of MRI-
guided needle sampling and/or wire localization of MRI-Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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guided biopsy is widely available in imaging centers in
the United States. Although the MRI-guided biopsy is
often used for MRI-detected lesions [9,10], MRI has lim-
itations such as its low specificity, the fact that it is a
time-consuming procedure, and the variation in its tech-
nical accuracy among institutions [9-12]. The availability
of MRI-guided biopsy is limited in Asia, including in
Japan [9-12]. On the other hand, CT-guided biopsy for
MDCT detected lesions is not practical due to radiation
exposure concerns [13-18].
The rationale for further modalities needed to evaluate
MDCT- or MRI-detected lesions is latent formation of
malignant tumors [19-25]. Since ultrasonography
involves no radiation exposure, its repeated use is feas-
ible. A second ultrasonography is performed in MDCT-
or MRI-detected lesions. This use of ultrasonography is
different from the initial ultrasonography involving the
screening of the whole breast, and is known as targeted
sonography or second-look sonography. When a lesion
is detected on targeted sonography, other options in
addition to MRI guidance are available, including sono-
graphically guided biopsy, surgical excision with sono-
graphic marking and follow-up with ultrasonography.
Targeted sonography is an important tool as a break-
through to the further examination; however, the detec-
tion rate with targeted sonography has varied in previous
reports [19-24].
MDCT has been employed for routine applications in
our institution since January 2004, and MRI in addition
to MDCT has been employed since 2010. Since 2011,
only MRI has been routinely used for the detection of
ductal lesions of breast cancer due to administrative rea-
son. In this study, we retrospectively reviewed our data
regarding MDCT- or MRI-detected lesions that under-
went targeted sonography followed by imaging-guided




We retrospectively reviewed the medical records of 695
patients with newly diagnosed breast cancer who con-
secutively underwent MDCT or MRI for preoperative
evaluation in a community hospital in Japan between
January 2004 and March 2011. Mammography and ultra-
sonography failed but MDCT or MRI detected 31 lesions
in the contralateral breast and 30 in the ipsilateral breast.
An ipsilateral breast lesion is defined as a lesion that is
in a different segment or more than 3 cm away from the
main tumor.
We performed targeted sonography in all 61 MDCT-
or MRI-detected lesions in 56 patients (8.1% in 695
patients). When targeted sonography identified MDCT-or MRI-detected lesions, we investigated cytologic or
pathologic outcomes. We followed up sonographically
negative lesions after consultation with the patient. Pa-
tient demographics and menopausal status were com-
pared between the pathologically confirmed and follow-
up groups. We compared the maximum tumor size and
depth:width ratio of lesions detected by targeted sonog-
raphy among benign, malignant and follow-up groups.Imaging acquisition and radiation exposure
MDCT was performed using a 16-detector row MDCT
scanner (SOMATOM 16, Siemens, Germany) set for
2 mm collimation, 120 kVp, and 180 mA. Scanning was
performed at 5 min and 70 seconds after the injection of
contrast material (Iopamiron 370 mg/ml, Nihon Scher-
ing K.K., Osaka, Japan). Axial, coronal and sagittal
images were examined, and multiplanar reconstruction
(MPR) and maximum intensity projection (MIP) of the
sagittal image and volume-rendering image were per-
formed to detect the ipsilateral ductal component and
breast cancer. The contralateral breast was evaluated on
an axial image. The weighted CT dose indexes (CTDIw)
were 7.8 mGy in plane, 14.04 mGy each in the early and
delayed phases and 35.88 mGy in total.
MRI was performed on a 1.5 T scanner (Achieva, Phil-
lips) with the use of a dedicated surface breast coil. The
imaging protocol consisted of an axial fat-suppressed
T2-weighted sequence in a spectral attenuated inversion-
recovery sequence, an axial T1-weighted sequence, an
axial diffusion-weighted sequence and an axial dynamic
three-dimentional fat-suppressed T1-weighted turbo
filed-echo sequence (enhanced T1 high resolution iso-
tropic volume examination). After the injection of con-
trast media, a sagittal contrast-enhanced high resolution
T1-weighted gradient-echo sequence was performed be-
tween 2 and 5 minutes of dynamic study. Coronal max-
imum intensity projection images were reconstructed
from a sagital contrast-enhanced high resolution T1-
weighted gradient-echo sequence.Breast imaging interpretation
MDCT and MRI images were independently interpreted
by one radiologist with knowledge of the clinical and
mammographic findings according to the BI-RADS MRI
lexicon. A lesion was considered positive if there were
focal and segmental enhancements, while diffuse and
multiple lesions in bilateral breasts, suggesting fibrocystic
changes, were considered negative.Sonography
Ultrasonographic examinations were performed on a
LOGIQ 500 (GE Healthcare) using an 11-MHz linear
transducer.









Mean age (SD) 59.1 (13.2) 48.4 (13.2) t = 2.4*
Menopausal status
Premenopausal 14 (33) 8 (73) Chi-square = 5.
Postmenopausal 28 (67) 3 (27) 6*
*p< .05, ns: not significant.
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We performed vacuum-assisted core needle biopsy
under ultrasound guidance using 11-gauge probes
(Mammotome Biopsys, Irvine, California) for definitive
pathological diagnosis.
Analysis
We used the t-test and chi-square test to compare
mean values between two groups. For comparisons
among malignant, benign and follow-up groups, we
used the chi-square test and univariate analysis of vari-
ance. For multiple comparisons among the three groups,
we used the Scheffé test. A value of p<0.05 was consid-
ered significant.
Ethical considerations
This study was approved by the institutional review
board of Kawaguchi Municipal Medical Center.
Results
Of all 61 MDCT- or MRI-detected lesions, 58 (95.1%) in
53 patients were identified by targeted sonography.
Pathologic diagnoses were obtained in 45 lesions, and we
followed up 13 lesions. A status of study lesions is shown
in Figure 1.
As for the 53 patients, the age and menopausal status
of the pathologically confirmed group and the follow-up
group are shown in Table 1. Patients in the pathologic-
ally confirmed group were significantly older and more
likely to be postmenopausal than those in the follow-up
group. There were no significant differences in the
follow-up period between the two groups (Table 1).
Example images of MDCT and targeted sonography
are shown in Figures 2, 3 and 4. Figure 2 shows a suspi-
cious lesion in the ipsilateral breast, and it is more thanMDCT/MRI-detected
targeted ultraso
US-Unidentified lesion












Figure 1 Status of Study Lesions.3 cm distant from the main lesion. MDCT shows linear
enhancement surrounded by fat tissues, while targeted
sonography depicts a hypoechoic lesion in the atrophic
thin breast with a size of 14 x 2 mm and abundant fat
tissues surrounding the lesion. Ductal carcinoma in situ
(DCIS) was suspected on the MDCT and ultrasonog-
raphy image findings. It is often difficult to keep the le-
sion visible during an ultrasound-guided biopsy. We
made an excision after marking on the skin of the lesion
under ultrasound. The pathologic finding of this lesion
was DCIS.
Figure 3 shows a clustered enhanced lesion in the ipsi-
lateral breast on MDCT. The lesion was 1.5 cm distant
from the nipple lower outer quadrant in the breast on
the MDCT. Targeted sonography showed a faintly
hypoechoic lesion as an enhanced area. We excised it
simultaneously with performing a lumpectomy of the
known breast cancer after sonographically guided mark-
ing because it was located in a difficult place to perform
sonographically guided biopsy. The pathologic finding of
the lesion was columnar cell hyperplasia.
Figure 4 showed a well-demarcated enhanced tumor
in the thin breast tissue which was 1.5 cm distant from lesions that underwent
nography (n = 61)












Figure 2 MDCT showed segmental enhancement on the ipsilateral breast. An enhanced lesion was depicted in the thin breast gland.
Targeted sonography detected a hypoechoic lesion in the thin breast gland, the size of which was 14x2 mm. Excisional biopsy was performed for
definitive diagnosis. Pathological diagnosis was ductal carcinoma in situ.
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2 mm. Targeted sonography depicted a hypoechoic mass
in the atrophic breast and sonographically guided biopsy
was performed under ultrasound guidance. The patho-
logic finding was hyperplasia.
Sonography-guided fine needle aspiration was per-
formed in 22 lesions, and a pathologic diagnosis was
made in 45 lesions. Of the 22 lesions, fine needle aspir-
ation cytology was benign or normal in 7, inadequate in
7, indeterminate in 2, suspicious for malignancy in 1,
and malignant in 5. For a pathological diagnosis, 30
lesions underwent sonographically guided biopsy, while
9 lesions underwent surgical biopsy during and before
the operation, 5 lesions had extended excisional ranges,
and one underwent core needle biopsy.
Pathologic examinations revealed benign in 20 (44%)
lesions and malignant in 25 lesions (56%), including one
lesion diagnosed as cancer at another hospital. Of the 20
benign tumors pathologically diagnosed in our hospital,
7 were hyperplasia, 5 were intraductal papillomatosis, 3Figure 3 MDCT showed clustered enhancement on the ipsilateral bre
difficult to differentiate the surrounding tissue. An excisional biopsy was pe
diagnosis. The pathological diagnosis was columnar cell hyperplasia.were fibrocystic change, 2 were fibroadenoma and one
was adenoma. Proliferation was not found in 2 lesions
with discharge in the dilated duct. Of 25 malignant
tumors, DCIS was found in 13 and invasive ductal car-
cinoma in 12 (Table 2). The mean follow-up period (SD)
of 56 patients was 940.2 (553.1) days.
The maximum diameter of the detected lesions as deter-
mined by targeted sonography is shown in Table 3. The
maximum diameter was under 5.0 mm in 26 lesions, 5.1-
10.0 mm in 25 lesions, 10.1-15.0 mm in 6 lesions, and over
15.1 mm in one lesion. The mean (SD) of the maximum
tumor size was 6.5 (3.8) mm. As the lesion over 15.1 mm
was suspected to be present in the image of one patient,
we measured the size of the hypoechoic lesion. There were
no significant differences in size among the malignant, be-
nign and follow-up groups (Table 3).
As shown in Table 4, the numbers of lesions with
depth:width ratios under and over 0.7 were 45 and 13,
respectively. There were no significant differences in the
depth:width ratio in the three groups (Table 4).ast. Targeted sonography detected a hypoechoic lesion, but it was
rformed at the same time as breast lumpectomy to obtain a definitive
Figure 4 MDCT showed enhanced focus on the contralateral breast. Targeted sonography showed a hypoechoic mass connecting to the
adjacent ducts, the size of which was 5x2 mm. Sonography-guided vacuum-assisted core needle biopsy was performed to obtain a definitive
diagnosis. The pathological diagnosis was hyperplasia.
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imaging strategy for MDCT- or MRI-detected lesions in
breast cancer (Figure 5).Discussion
Approximately 95% of MDCT- or MRI-detected lesions
were identified by targeted sonography in this study. The
results suggest that targeted sonography, as a diagnostic
imaging strategy, is a practical modality for all MDCT-
or MRI-detected lesions, allowing more options for fur-
ther evaluation. In other words, targeted sonography nar-
rows down the number of lesions that really require
MRI-guided biopsy.
Pathologic diagnosis is required for MDCT- or MRI-
detected lesions because the imaging finding is not the
definitive diagnosis. The MDCT- or MRI-detected lesions
are not palpable; therefore biopsy is performed under im-
aging guidance. Regardless of the availability of MRI-
guided biopsy, it is practical that targeted sonography is
the first procedure to be considered for MDCT- or MRI-
detected lesions. The sonographically guided technique
provides an advantage. Ultrasonography is the most fre-
quently used and easy-to-use diagnostic tool in daily
practice. Once the lesion is depicted on sonography,Table 2 Pathologic findings in 45 lesions
Malignant 25
Ductal carcinoma in situ 13







No malignancy 2targeted sonography provides more options for further
evaluation including sonographically guided biopsy, sur-
gical excision after marking under sonography and
follow-up with ultrasonography.
The guiding principle in diagnosis depends on
whether the lesion is detected with targeted sonography.
Because these lesions are difficult to depict by initial
mammography or ultrasonography, the detection rate of
lesions with targeted sonography varies among institu-
tions [19-24]. There are tips for detecting MDCT- or
MRI-detected lesions with targeted sonography. First, the
location difference due to the position should be consid-
ered. MRI is performed in the prone position, while
MDCT is performed in the supine or prone position, de-
pending on the institutions. We performed MDCT in the
prone position. The positional difference is larger in the
prone position than in the supine position. Attention
should be paid to the deviation caused by the arm pos-
ition even in the supine position. Second, the anatomical
positional relation is important. The distance from the
nipple, the thickness of the breast gland and the depth of
the tumor in the gland should all be referenced. As the
nipple is a useful milestone, we use it as a center with the
medial or lateral and caudal or cranial directions used to
describe locations in reference to it. Breast thickness isTable 3 Maximum tumor size of the lesion detected by
targeted sonography
Malignant Benign Follow-up Total p
Maximum diameter (mm)
~5.0 7 (28) 11 (55) 8 (62) 26 (45) ns
5.1~10.0 13 (52) 8 (40) 4 (31) 25 (43)
10.1~15.0 4 (16) 1 (5) 1 (8) 6 (10)
15.1~ 1 (4) 0 (0) 0 (0) 1 (2)
Total 25 (100) 20 (100) 13 (100) 58 (100)
Mean (SD) 7.7 (4.8) 5.5 (2.3) 5.4 (2.6) 6.5 (3.8)
Table 4 Depth:width ratio of the lesion detected by
targeted sonography
Malignant Benign Follow-up Total P
0.7≧ 17 (68) 18 (90) 10 (77) 45 (78) ns
0.7< 8 (32) 2 (10) 3 (23) 13 (22)
Total 25 (100) 20 (100) 13 (100) 58 (100)
Mean (SD) .58 (.24) .53 (.16) .57 (.21) .56 (.21)
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changes. Third, tumor size, the morphology of the lesion
and the structure of the breast gland surrounding the le-
sion are also useful information for predicting the pos-
itional difference. To determine whether the enhanced
lesion is nodular, linear or segmental, and whether the
breast structure surrounding the lesion is fat or abundant
in the breast gland, it is helpful to perform targeted son-
ography. Also, these attributes are not affected by pos-
itional changes. These techniques are helpful to improve
the detection rate.
There were no significant differences in the size or the
depth:width ratio in the benign, malignant, and follow-
up groups in our study. The mean tumor size was
6.5 mm and the mean depth:width ratio was 0.56, sug-
gesting a relatively small and flat lesion. The MDCT or
MRI detected lesion, however, has few distinct features;
thus it may be found falsely negative on the initial im-
aging findings. We also performed cytology in 22 lesions
in order to obtain a diagnosis. It is often difficult to ob-
tain a large enough sample with fine needle aspiration,
and the reliability of this technique is poor if we fail to
obtain a sufficient sample. Also, cytology is not sensitive












Figure 5 Diagnostic Imaging Strategy for MRI- or MDCT-Detected LesIn this study, more than half of the pathologic findings
were revealed to be malignant, and half of them were
DCIS. The higher probability of malignancy requires pre-
operative assessment of the extent of the disease because
it may alter the surgical management. We reported that
MDCT contributed to the detection of occult breast can-
cer in 2.6% of contralateral breasts [26]. MDCT or MRI
in conjunction with targeted sonography is a useful tech-
nique for detecting early carcinoma in women who are
at increased breast cancer risk.
The pathologic findings revealed that there was no
proliferation in 2 out of 45 lesions with discharge in the
dilated duct. Because no proven proliferating lesion was
found, concern remains that the lesion observed might
not be the MDCT- or MRI-detected lesion. La Trenta
suggests that it is not unlikely that undetected lesions
are malignant [21]. It is difficult to perform core biopsy
or small excisional biopsy when the lesion is not
detected. At the same time, wide excisional biopsy is ra-
ther excessive treatment. A careful follow-up is always
necessary to avoid delayed or missed diagnoses. The
mean follow-up period for lesions unidentified by tar-
geted sonography was 916 days in this study. So far there
are no newly developed lesions or tumor growth.
It has recently been reported that real-time virtual
sonography (RVS) can synchronize a sonography image
and an MRI or CT image of the same section in real
time [12,27]. Accurate comparison of individual posi-
tions is a useful technique for confirming a lesion. Ultra-
sonography greatly depends on the technique,
knowledge and experience of the operator. RVS reduces
the differences among operators and increases the phy-
sician’s confidence about the MDCT- or MRI-detected
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option or, at the very least, follow-up is required.
We found that significantly more older patients had
pathologically confirmed tumors, and they were more
likely to be postmenopausal than those in the follow-up
group. It is reported that younger patients have higher
background parenchymal enhancement and a higher
proportion of nodular parenchymal enhancement pat-
terns [28-30]. Since younger and premenopausal groups
were suspected to have fibroglandular changes, these
patients require follow-up.
Our study has several limitations. It is a retrospective
single-center study. Ten lesions with cytological diagno-
sis were not pathologically evaluated. Although fine nee-
dle aspiration cytology has high specificity and positive
predictive value for mass lesions [31-33], it is difficult to
obtain enough cells for MDCT- or MRI-detected lesions,
particularly if it is low-grade or papillary lesion. We used
fine needle aspiration as the initial diagnostic modality to
provide valuable clues, but the study findings need to be
interpreted with caution. We have followed-up with
these patients.
Conclusion
Targeted sonography is a useful modality for the evalu-
ation of new unsuspected lesions found on MDCT or
MRI in patients with breast cancer. By considering the
previous MDCT or MRI findings and the location differ-
ence due to the position, the detection rate of targeted
sonography can be improved. We achieved a 95% detec-
tion rate in this study. As a diagnostic imaging strategy,
targeted sonography is a practical consideration for all
MDCT- or MRI-detected lesions.
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